DUB:OVXA - Euronext Dublin - IE00B4XVDC01 - Common Stock - Currency: EUR
DUB:OVXA (4/30/2025, 7:00:00 PM)
0.0105
0 (-8.7%)
The current stock price of OVXA.I is 0.0105 EUR. In the past month the price decreased by -57.14%. In the past year, price decreased by -93.4%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 66.82 | 724.07B | ||
LLY.DE | ELI LILLY & CO | 62.54 | 677.62B | ||
ZEG.DE | ASTRAZENECA PLC | 17.49 | 391.58B | ||
JNJ.DE | JOHNSON & JOHNSON | 15.53 | 330.87B | ||
NOV.DE | NOVO NORDISK A/S-B | 20.04 | 269.54B | ||
SAN.PA | SANOFI | 14.49 | 238.71B | ||
SNW.DE | SANOFI | 14.28 | 235.26B | ||
1SAN.MI | SANOFI | 12.19 | 229.14B | ||
1MRKX.MI | MERCK & CO. INC. | 10.85 | 186.97B | ||
6MK.DE | MERCK & CO. INC. | 10.79 | 185.96B | ||
PFE.DE | PFIZER INC | 7.8 | 120.80B | ||
1PFE.MI | PFIZER INC | 7.43 | 115.02B |
Ovoca Bio Plc is a clinical-stage biopharmaceutical company, which engages in the women's health, clinical development and commercial planning of BP-101, and novel treatment for women with hypoactive sexual desire disorder (HSDD). The firm is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). The company is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. The company is also developing a new treatment for women affected by low libido or sex drive. The company owns a patent portfolio that provides effective protection of its technology. The firm operates in Ireland, the United Kingdom and Russia.
OVOCA BIO PLC
17 Pembroke Street, Upper
DUBLIN DUBLIN IE
Employees: 5
Company Website: https://ovocabio.com/
Investor Relations: http://www.ovocabio.com/results-reports-presentations/
Phone: 35316619819
The current stock price of OVXA.I is 0.0105 EUR. The price decreased by -8.7% in the last trading session.
The exchange symbol of OVOCA BIO PLC is OVXA and it is listed on the Euronext Dublin exchange.
OVXA.I stock is listed on the Euronext Dublin exchange.
OVOCA BIO PLC (OVXA.I) has a market capitalization of 928.83K EUR. This makes OVXA.I a Nano Cap stock.
OVOCA BIO PLC (OVXA.I) currently has 5 employees.
OVOCA BIO PLC (OVXA.I) has a resistance level at 0.02. Check the full technical report for a detailed analysis of OVXA.I support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OVXA.I does not pay a dividend.
OVOCA BIO PLC (OVXA.I) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.06).
ChartMill assigns a technical rating of 1 / 10 to OVXA.I. When comparing the yearly performance of all stocks, OVXA.I is a bad performer in the overall market: 98.96% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to OVXA.I. While OVXA.I has a great health rating, there are worries on its profitability.
Over the last trailing twelve months OVXA.I reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 9.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -151.63% | ||
ROE | -210% | ||
Debt/Equity | 0 |